FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

LAPOINTE ANTHONY GREGG RIGEL PHARMACEUTICALS INC [RIGL] X_Director IO% Owner (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) Offi								5 Deletionalia of Demontine Demon(a)	4- T		
RIGEL PHARMACEUTICALS, INC., 1180 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Group FilingCheck Applicable Line) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group FilingCheck Applicable Line) SOUTH SAN FRANCISCO, CA 94080 7. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned I.Title of Security 2. Transaction 3. Transaction 4. Securities Acquired 5. Amount of Securities Beneficially Owned I.Title of Security 2. Transaction 24. Deemed 3. Transaction 4. Securities Acquired 5. Amount of Securities Beneficially Owned I.Title of Security 0. Month/Day/Year 10/Jay/Year 10. Transaction 10. Transaction 4. Securities Acquired 5. Amount of Securities Beneficially 6. 7. Nature Instr. 3) 0. Month/Day/Year 10. Month/Day/Year 10. Instr. 3, 4 and 5) 10. Instr. 3 and 4) 10. Ownership 10. Ownership	1. Name and Address of Reporting Person ⁺ LAPOINTE ANTHONY GREGG				· ·						
In Finisheiten, Date Original Field with Day (teal) SOUTH SAN FRANCISCO, CA 94080 (City) (State) (City) (State) (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect	RIGEL PHARMACEUTICALS, INC., 1180	3. Date of Earnest Transaction (Wonth/Day/Tear)						ther (specify belo	ow)		
1. Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2.A. Deemed Execution Date, if (Month/Day/Year)3. Transaction Code (Instr. 8)4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)6.7. Nature of Indirect Beneficial Ownership Ownership Or Indirect		4. If Amendment, Date Original Filed(Month/Day/Year)						_X_Form filed by One Reporting Person			
(Instr. 3)Date (Month/Day/Year)Execution Date, if any (Month/Day/Year)Code 	(City) (State) (Zip)		Table I - No	on-De	rivative S	Securitie	s Acqu	ired, Disposed of, or Beneficially Ow	ned		
Code V Amount (D) Price (Instr. 4)	(Instr. 3) Date	Execution Date, if r) any	Code (Instr. 8)		(A) or D (Instr. 3,	isposed of 4 and 5) (A) or	of (D)	Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Conversion	(Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion)	n of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Underlying		Derivative Security (Instr. 5)	Securities Beneficially Owned Following	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	v	(A)		Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 3.8	10/31/2017		А		80,000		<u>(1)</u>	10/31/2027	Common Stock	80,000	\$ 0	80,000	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LAPOINTE ANTHONY GREGG RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	Х						

Signatures

 /s/ Dolly Vance (Attorney-in-Fact)
 11/02/2017

 -**Signature of Reporting Person
 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.